Skip to main content

Change in Preferred Drug List Status for Generic Fluticasone HFA Products

Last updated on

The Texas Vendor Drug Program (VDP) has removed the non-preferred status from the authorized generic (AG) fluticasone HFA and brand name QVAR Redihaler products on the Preferred Drug List (PDL). The removal is due to the discontinuation of the preferred brand-name product Flovent HFA. These changes allow providers to prescribe the authorized generic (AG) fluticasone HFA and brand-name QVAR Redihaler products without requiring a PDL prior authorization.

The following drugs were removed:

National Drug CodeDrug Name
66993007896Fluticasone prop HFA 44 MCG
66993007996Fluticasone prop HFA 110 MCG
66993008096 Fluticasone prop HFA 220 MCG
59310030240QVAE Redihaler 40 MCG
59310030480QVAE Redihaler 80 MCG

Important: On the January 2025 PDL, fluticasone HFA authorized generic (AG) will no longer be available without a PDL prior authorization. The board recommended the following as preferred products:

  • Airduo Respiclick
  • Arnuity Ellipta
  • Asmanex HFA
  • Advair Diskus

Other preferred products in the Glucocorticoids, Inhaled PDL drug class include the following:

  • Advair Diskus
  • Advair HFA
  • Asmanex Twisthaler
  • Budesonide respules
  • Dulera
  • Pulmicort Flexhaler
  • Symbicort

VDP will implement the July 2024 PDL decisions on the January 2025 PDL. Refer to the DUR Board Documents page for the PDL recommendations and decisions.

Email vdp-formulary@hhsc.state.tx.us with comments or questions.